Search

Your results

Showing 10 of 22 results

In April 2023, the European Commission adopted regulatory proposals introducing a Unitary Supplementary Protection Certificate (SPC) and a centralised assessment procedure for SPCs for medicinal products. This study analyses the potential impacts of these proposals on access to medicines, the administrative burden to applicants and the cost to national health systems. This document was prepared by Policy Department for Citizens' Rights and Constitutional Affairs at the request of the JURI Committee ...

On 26 Avril 2023, the European Commission put forward a 'pharmaceutical package' to revise the EU's pharmaceutical legislation and make medicines more available, accessible and affordable, while supporting the competitiveness and attractiveness of the EU pharmaceutical industry, with higher environmental standards. The package includes proposals for a new directive and a new regulation, which would replace the existing pharmaceutical legislation, including the legislation on medicines for children ...

Plenary round-up – January I 2023

At a Glance 20-01-2023

The highlights of the January I 2023 plenary session were debates on the conclusions of the European Council meeting of 15 December 2022 and the presentation of activities planned under the Swedish Presidency of the Council of the European Union. The session opened with a ceremony marking the 30th anniversary of the single market, followed by a debate with the Council and Commission on the matter. Debates were held on the surge of respiratory infections and the shortage of medication in Europe; on ...

This briefing follows up the commitments made by the commissioner since 2019.

As part of building a European Health Union, as well as in response to the Covid 19 pandemic, the European Commission proposed in November 2020 to reinforce the European Medicines Agency's role in crisis preparedness and the management of medicines and medical devices. The proposed regulation seeks to better anticipate possible shortages and to ensure timely development of high-quality medicinal solutions, to allow the EU to react to health crises more quickly, efficiently, and in a coordinated manner ...

Nanoparticles lie at the heart of a new method for delivering medicines inside the body – and they were crucial to the success of the Covid-19 mRNA vaccines. This new drug delivery method and others could transform the way we treat disease, potentially boosting the treatment of Alzheimer's, Parkinson's and HIV, among others. Insulin and Covid-19 vaccines might even become available as pills. Can the European Union stay on top of this trend? And what challenges lie ahead?

On 11 November 2020, the European Commission adopted a proposal to strengthen the European Medicines Agency (EMA). The proposed regulation would allow the EMA, among other things, to better anticipate possible shortages of medicinal products and ensure their timely development, with the aim of improving the EU's capacity to respond to health emergencies. The European Parliament's Committee on the Environment, Public Health and Food Safety adopted its report on 22 June 2021. This is due to be voted ...

Access to medicinal products

Study 01-05-2021

There are many factors that can prevent a patient from being able to obtain the medicine they need, ranging from selective marketing decisions by companies to products being too expensive or pharmacy stock-outs. Because of national differences in health systems and market characteristics, access to medicine is not evenly distributed across the European Union. In response to observed problems with access to medicine, in 2017 the European Parliament adopted a resolution containing 58 recommendations ...

What if we could renew all our cells?

At a Glance 20-11-2020

Regenerative medicine (RM) is an interdisciplinary field that applies engineering and life science techniques to restore tissues and organs damaged by age, disease or trauma, as well as those with congenital defects. Promising data supports the future capability of using RM across a wide array of organ systems and contexts, including surface wounds, cardiovascular diseases and traumas and treatments for certain types of cancer.